Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1918583 | 0.91 | CYP3A4 (0.39) | CYP3A4CYP2C8 | |
| SCHEMBL1918518 | 0.91 | CYP3A4 (0.41) | CYP3A4KCNH2 | |
| SCHEMBL1918933 | 0.85 | — | — | |
| SCHEMBL1919012 | 0.83 | CYP3A4 (0.42) | CYP3A4CYP2C8 | |
| SCHEMBL2142748 | 0.83 | CYP2C8 (0.62) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL1919314 | 0.82 | CYP3A4 (0.40) | CYP3A4CYP2C8KCNH2 | |
| SCHEMBL1920430 | 0.82 | CYP2C8 (0.46) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL14323750 | 0.82 | CYP3A4 (0.44) | CYP3A4CYP2C8 | |
| SCHEMBL2431623 | 0.81 | ALDH1A1 (0.45) | CYP3A4CYP2C8KCNH2NR1I2 | |
| SCHEMBL2141940 | 0.80 | CYP3A4 (0.40) | CYP3A4CYP2C8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2545042-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2013-01-16 | — | — | EP | disclosed |
| WO-2011112191-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2011-09-15 | — | — | WO | disclosed |
| EP-2326633-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | Bristol-Myers Squibb Company (US) | 2011-06-01 | — | — | EP | disclosed |
| WO-2010030592-A1 | COMPOUNDS FOR THE TREATMENT OF HEPATITIS C | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-03-18 | — | — | WO | disclosed |